For decades, measles has been one of the most contagious—and preventable—diseases on the planet. Vaccination remains the gold standard for protection, but for those exposed to the virus, the options have long been limited: hope for the best, isolate quickly, or rely on post-exposure prophylaxis like immunoglobulin, which offers only partial protection. Now, a breakthrough in antibody research may change that. Scientists at the La Jolla Institute for Immunology (LJI) and Columbia University have uncovered how a specific human antibody can neutralize the measles virus before it infects a host cell, potentially paving the way for a post-exposure treatment that could block infection entirely.
The discovery hinges on a rare and precise mechanism: the antibody, dubbed mAb 77, binds to a critical site on the measles virus’s fusion protein, preventing the virus from fusing with human cells. This is not just a theoretical advance. In laboratory and rodent models, the antibody has already demonstrated the ability to reduce viral loads by hundreds of times, offering a tantalizing glimpse into a future where measles could be treated after exposure, not just prevented before it.
As measles cases surge globally due to declining vaccination rates and the rise of immunocompromised populations, the stakes for this research could not be higher. The World Health Organization declared measles eliminated in the United States in 2000, but outbreaks have returned with alarming frequency in recent years. The Centers for Disease Control and Prevention reported a 50% increase in measles cases in the U.S. From 2022 to 2023, underscoring the urgent need for new tools to combat the virus.
The research, published in the journal Science, marks a pivotal step toward developing the world’s first measles-specific treatment. Unlike vaccines, which must be administered before exposure, this antibody-based approach could offer a lifeline to those already at risk—including infants too young for vaccination, immunocompromised individuals, and travelers in high-risk regions. The next critical phase is translating these findings into clinical trials, where researchers will test the safety and efficacy of the antibody in humans.
A New Target for Measles
The measles virus is a master of cellular infiltration. Once airborne particles enter the body, the virus hijacks the machinery of human cells, using a specialized protein to fuse with the cell membrane and initiate infection. This fusion process is the Achilles’ heel of the virus—and the precise target of the newly identified antibody.
Using advanced imaging techniques, including cryo-electron microscopy, LJI researchers visualized the moment the antibody binds to the virus’s fusion protein, locking it in a non-infectious state. “We’ve essentially found a way to stop the virus in its tracks,” said one of the study’s lead authors, whose work was highlighted in a June 2024 press release from LJI. “This antibody doesn’t just weaken the virus; it prevents it from ever gaining a foothold in the cell.”
The implications are profound. Current post-exposure prophylaxis for measles relies on immunoglobulin, a blood-derived product that contains a mix of antibodies. While it can reduce the severity of symptoms, it is not consistently effective, especially in immunocompromised patients. The new antibody, however, is highly specific and potent, offering a more targeted and potentially more reliable defense.
Who Stands to Benefit?
The potential impact of this breakthrough extends far beyond the laboratory. Several groups are particularly vulnerable to measles and would benefit most from a post-exposure treatment:
- Infants too young for vaccination: Measles can be deadly in children under one year old, who are too young to receive the MMR vaccine.
- Immunocompromised individuals: People undergoing chemotherapy, HIV patients, and others with weakened immune systems cannot be vaccinated and are at high risk of severe disease.
- Travelers and healthcare workers: Those frequently exposed to international travel or high-risk environments could use a rapid, reliable treatment option.
Currently, the only recourse for exposed individuals is vaccination within 72 hours or immunoglobulin within six days, neither of which guarantees protection. The new antibody could offer a more robust alternative, particularly in regions where measles outbreaks are common.
What’s Next for the Research?
The path from laboratory discovery to clinical application is long, and rigorous. Researchers must first demonstrate the safety and efficacy of the antibody in human trials. Early data from rodent models are promising, but human studies will be essential to confirm these results.
According to LJI, the next phase involves scaling up production of the antibody and preparing for Phase I clinical trials, which typically assess safety and dosage. If successful, Phase II and III trials would evaluate efficacy in preventing infection after exposure. The timeline for approval is uncertain, but given the urgency of the public health need, regulatory agencies may prioritize expedited reviews.
Why This Matters Now
Measles is not just a historical relic. In 2023, the virus caused nearly 100,000 deaths worldwide, mostly in children under five, according to the World Health Organization. The resurgence of measles in the U.S. And other developed nations is a stark reminder that no community is immune to preventable diseases. Vaccination remains the cornerstone of measles prevention, but a post-exposure treatment would provide an additional layer of protection, especially in vulnerable populations.
For now, public health officials continue to urge vaccination, particularly for children, healthcare workers, and those planning international travel. The CDC recommends two doses of the MMR vaccine for children, with the first dose at 12–15 months and the second at 4–6 years. Adults without proof of immunity should also get vaccinated.
Where to Find Official Updates
For the latest information on measles prevention and treatment, consult the following resources:
- Centers for Disease Control and Prevention (CDC) – Measles
- World Health Organization (WHO) – Measles
- La Jolla Institute for Immunology – Measles Research
As researchers move closer to clinical trials, the hope is that this breakthrough will not only save lives but also restore confidence in our ability to control even the most formidable infectious diseases.
A Look Ahead
The next major milestone will be the initiation of human clinical trials, likely within the next 12–24 months. If successful, the antibody could be approved for emergency use in high-risk settings, offering a critical tool in the fight against measles. Until then, vaccination remains the best defense, and public health experts urge everyone to stay up to date with their MMR shots.
For those interested in supporting or participating in this research, the La Jolla Institute for Immunology and Columbia University are leading the effort. Stay tuned for updates as this story unfolds—because the future of measles treatment may hinge on the science unfolding right now.
Have you or someone you know been affected by measles? Share your story or questions in the comments below, and let’s keep the conversation going.
